What Convexia does
Convexia is an AI-driven pharma company that uses AI agents to identify, evaluate and accelerate overlooked drug candidates from academic institutions, early-stage companies and abandoned pharmaceutical IP. It combines automated scientific analysis with expert human review at each decision point.
Key capabilities
Convexia's workflow spans several stages: an asset discovery agent scans globally for high-potential candidates across structured and unstructured data; scientific evaluation runs more than 50 custom ML models assessing properties such as binding affinity, toxicity, pharmacokinetics, immunogenicity and mechanism of action; and market and operational layers rank assets by unmet need, IP strength and execution risk. A success-prediction model benchmarks go/no-go decisions against historical analogs, and domain scientists and a KOL roundtable validate findings. The company uses modular agents and semi-supervised learning to work with scarce biomedical data, emphasizing human-in-the-loop design.
Who it's for
Convexia serves pharmaceutical companies, biotech firms and investors evaluating drug candidates, with a long-term goal of operating the full drug lifecycle.